$393 Million is the total value of Opaleye Management Inc.'s 47 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDXS | CODEXIS INC | $30,012,000 | +19.1% | 1,750,000 | 0.0% | 7.64% | +17.1% | |
| LOXO | LOXO ONCOLOGY | $29,895,000 | -1.5% | 175,000 | 0.0% | 7.61% | -3.2% | |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $16,262,000 | -1.6% | 420,000 | 0.0% | 4.14% | -3.3% | |
| AGIO | AGIOS PHARMACEUTICALS | $10,025,000 | -8.4% | 130,000 | 0.0% | 2.55% | -10.0% | |
| PTCT | PTC THERAPEUTICS INC | $8,460,000 | +39.4% | 180,000 | 0.0% | 2.15% | +37.0% | |
| AMAG | AMAG PHARMACEUTICALS INC | $8,400,000 | +2.6% | 420,000 | 0.0% | 2.14% | +0.8% | |
| XNCR | XENCOR INC | $6,140,000 | -7.8% | 180,000 | 0.0% | 1.56% | -9.4% | |
| RARE | ULTRAGENYX PHARMACEUTICALS INC | $6,107,000 | -0.7% | 80,000 | 0.0% | 1.55% | -2.4% | |
| CDTX | CIDARA THERAPEUTICS INC | $5,280,000 | -15.4% | 1,200,000 | 0.0% | 1.34% | -16.8% | |
| BLRX | BIOLINERX LTDsponsored adr | $267,000 | +20.3% | 250,000 | 0.0% | 0.07% | +19.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.